DCN and urinary bladder carcinoma: Moreover, we provided the first evidence for a role of decorin in regulating ligand-dependent stability of IRS-1 suggesting the novel hypothesis that decorin may regulate IGF-IR-dependent biological responses in bladder cancer cells not only by directly affecting receptor activation but also modulating the stability of downstream signaling proteins (77).